Search

Your search keyword '"Pierik M"' showing total 500 results
Start Over Author "Pierik M"
500 results on '"Pierik M"'

2. P189 Lifestyle and psychosocial factors in IBD; prevalence and patients’ perspective

Author

Demers, K, primary, Hendrix, E M B, additional, Rezazadeh Ardabili, A, additional, Bredero, Q M, additional, van Bodegraven, A A, additional, van der Horst, D, additional, Jonkers, D M A E, additional, Kimman, M L, additional, Mujagic, Z, additional, Romberg-Camps, M J, additional, Römkens, T E H, additional, Scherpenzeel, M P, additional, Schroevers, M J, additional, Stassen, L P S, additional, West, R L, additional, Dijkstra, G, additional, and Pierik, M J, additional

Published
2024
Full Text
View/download PDF

5. P818 Imaging-based preoperative body composition is associated with the risk of postoperative complications and postoperative endoscopic recurrence in patients with Crohn’s disease

Author

Bak, M, primary, Demers, K, additional, van Ruler, O, additional, Pierik, M J, additional, van der Bilt, J D W, additional, Romberg-Camps, M, additional, Dijkstra, G, additional, Duijvestein, M, additional, van der Marel, S, additional, Maljaars, P W J, additional, Buskens, C J, additional, Bakers, F C H, additional, van Dijk, D P J, additional, Brecheisen, R, additional, Bongers, B C, additional, van Rossum, E F C, additional, de Witte, D, additional, Jansen, S V, additional, Jharap, B J H, additional, Horjus, C S, additional, van Schaik, F D M, additional, West, R L, additional, de Boer, N K H, additional, van der Woude, C J, additional, Stassen, L P S, additional, and de Vries, A C, additional

Published
2024
Full Text
View/download PDF

9. P946 Real life management of patients with active perianal fistulizing Crohn’s disease (ALERT-CD study)

Author

Bak, M, primary, Stassen, L, additional, Buskens, C, additional, Pronk, A, additional, van der Bilt, J, additional, Gecse, K, additional, de Boer, N, additional, Witjes, C, additional, Fitzpatrick, C, additional, Nissen, L, additional, Verdaasdonk, E, additional, Pierik, M, additional, Breukink, S, additional, Gillissen, L, additional, Bloemen, J, additional, West, R, additional, Kortekaas, R, additional, Mares, W, additional, de Jong, G, additional, Jansen, S, additional, Bloemendaal, B, additional, Sikkema, M, additional, Zimmerman, D, additional, Peeters, K, additional, van der Meulen- de Jong, A, additional, van Schaik, F, additional, Richir, M, additional, van Dongen, K, additional, Duijvestein, M, additional, Hoogenboom, F, additional, Visschedijk, M, additional, de Vries, A, additional, and van Ruler, O, additional

Published
2024
Full Text
View/download PDF

10. Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors

Author

Janssen, L. M., primary, Rezazadeh Ardabili, A., additional, Romberg‐Camps, M. J. L., additional, Winkens, B., additional, van den Broek, R. J., additional, Hulst, J., additional, Verwijs, H. J. A., additional, Keszthelyi, D., additional, Jonkers, D. M. A. E., additional, van Bodegraven, A. A., additional, Pierik, M. J., additional, and Mujagic, Z., additional

Published
2023
Full Text
View/download PDF

11. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease

Author

Straatmijer, T., Biemans, V.B.C., Moes, D.J.A.R., Hoentjen, F., ter Heine, R., Maljaars, P.W.J., Theeuwen, R., Pierik, M., Duijvestein, M., van der Meulen-de Jong, A.E.E., Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), and RS: NUTRIM - R2 - Liver and digestive health

Subjects
Crohn's disease, All institutes and research themes of the Radboud University Medical Center, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Physiology, Gastroenterology, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Ustekinumab, Pharmacokinetics, SUBCUTANEOUS USTEKINUMAB, THERAPY, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Inflammatory bowel disease, SERUM
Abstract

Contains fulltext : 293034.pdf (Publisher’s version ) (Open Access) OBJECTIVE: It is unknown whether ustekinumab (UST) levels can predict clinical outcomes in Crohn's disease (CD) patients. We assessed the exposure-response relationship of UST trough concentrations with biochemical outcomes at week 24 in a prospective, real-world setting. METHODS: We performed a prospective study in patients with CD starting UST in four academic centres in the Netherlands. All patients received a weight-adjusted intravenous (IV) UST induction dose, followed by one subcutaneous (SC) dose of 90 mg UST at 8 weeks. Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks. Individual UST concentration time course during treatment were estimated using a population pharmacokinetic (PK) model. Quartile analysis and logistic regression were performed to analyse if UST concentrations at week 8 were associated with biochemical remission rates at week 24 (C-reactive protein (CRP) ≤ 5 mg/L and / or faecal calprotectin (FC) ≤ 250 mg/kg). RESULTS: In total, 124 patients with CD were included. Patients achieving biochemical remission at week 12 and 24 had significantly higher UST levels at week 8 compared to patients without biochemical remission (6.6 µg/mL versus 3.9 µg/mL, P

Published
2023

13. Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome

Author

Kalla, R., Adams, A. T., Nowak, J. K., Bergemalm, D., Vatn, S., Ventham, N. A., Kennedy, N. A., Ricanek, P., Lindstrom, J., Söderholm, Johan D, Pierik, M., DAmato, M., Gomollon, F., Olbjorn, C., Richmond, R., Relton, C. L., Jahnsen, J., Vatn, M. H., Halfvarson, J., Satsangi, J., Kalla, R., Adams, A. T., Nowak, J. K., Bergemalm, D., Vatn, S., Ventham, N. A., Kennedy, N. A., Ricanek, P., Lindstrom, J., Söderholm, Johan D, Pierik, M., DAmato, M., Gomollon, F., Olbjorn, C., Richmond, R., Relton, C. L., Jahnsen, J., Vatn, M. H., Halfvarson, J., and Satsangi, J.

Abstract

Background Epigenetic alterations may provide valuable insights into gene-environment interactions in the pathogenesis of inflammatory bowel disease [IBD]. Methods Genome-wide methylation was measured from peripheral blood using the Illumina 450k platform in a case-control study in an inception cohort (295 controls, 154 Crohns disease [CD], 161 ulcerative colitis [UC], 28 IBD unclassified [IBD-U)] with covariates of age, sex and cell counts, deconvoluted by the Houseman method. Genotyping was performed using Illumina HumanOmniExpressExome-8 BeadChips and gene expression using the Ion AmpliSeq Human Gene Expression Core Panel. Treatment escalation was characterized by the need for biological agents or surgery after initial disease remission. Results A total of 137 differentially methylated positions [DMPs] were identified in IBD, including VMP1/MIR21 [p = 9.11 x 10(-15)] and RPS6KA2 [6.43 x 10(-13)], with consistency seen across Scandinavia and the UK. Dysregulated loci demonstrate strong genetic influence, notably VMP1 [p = 1.53 x 10(-15)]. Age acceleration is seen in IBD [coefficient 0.94, p < 2.2 x 10(-16)]. Several immuno-active genes demonstrated highly significant correlations between methylation and gene expression in IBD, in particular OSM: IBD r = -0.32, p = 3.64 x 10(-7) vs non-IBD r = -0.14, p = 0.77]. Multi-omic integration of the methylome, genome and transcriptome also implicated specific pathways that associate with immune activation, response and regulation at disease inception. At follow-up, a signature of three DMPs [TAP1, TESPA1, RPTOR] were associated with treatment escalation to biological agents or surgery (hazard ratio of 5.19 [CI: 2.14-12.56], logrank p = 9.70 x 10(-4)). Conclusion These data demonstrate consistent epigenetic alterations at diagnosis in European patients with IBD, providing insights into the pathogenetic importance and translational potential of epigenetic mapping in complex disease., Funding Agencies|European Commission [2858546]; Wellcome Trust [WT097943MA]

Published
2023
Full Text
View/download PDF

14. Assessing comprehensive remission for Ulcerative Colitis in clinical practice : International consensus recommendations

Author

Schreiber, S. W., Danese, S., Dignass, A., Domènech, E., Fantini, M., Ferrante, M., Halfvarson, Jonas, Hart, A., Magro, F., Lees, C., Leone, S., Pierik, M., Field, P., Schofield, H., Peyrin-Biroulet, L., Schreiber, S. W., Danese, S., Dignass, A., Domènech, E., Fantini, M., Ferrante, M., Halfvarson, Jonas, Hart, A., Magro, F., Lees, C., Leone, S., Pierik, M., Field, P., Schofield, H., and Peyrin-Biroulet, L.

Published
2023
Full Text
View/download PDF

15. Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease

Author

Kreijne, J. E., Goetgebuer, R. L., Erler, N. S., De Boer, N. K., Siebers, A. G., Dijkstra, G., van Kemenade, F. A., Hoentjen, F., Oldenburg, B., van der Meulen, A. E., Ponsioen, C. I.J., Pierik, M. J., van der Woude, C. J., de Vries, A. C., Kreijne, J. E., Goetgebuer, R. L., Erler, N. S., De Boer, N. K., Siebers, A. G., Dijkstra, G., van Kemenade, F. A., Hoentjen, F., Oldenburg, B., van der Meulen, A. E., Ponsioen, C. I.J., Pierik, M. J., van der Woude, C. J., and de Vries, A. C.

Abstract

Background: Women with inflammatory bowel disease (IBD) are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+). Aim: To assess the association between cumulative exposure to immunomodulators (IM) and biologic agents (BIO) for IBD and CIN2+. Methods: Adult women diagnosed with IBD before December 31st 2016 in the Dutch IBD biobank with available cervical records in the nationwide cytopathology database were identified. CIN2+ incidence rates in IM- (i.e., thiopurines, methotrexate, tacrolimus and cyclosporine) and BIO- (anti-tumour necrosis factor, vedolizumab and ustekinumab) exposed patients were compared to unexposed patients and risk factors were assessed. Cumulative exposure to immunosuppressive drugs was evaluated in extended time-dependent Cox-regression models. Results: The study cohort comprised 1981 women with IBD: 99 (5%) developed CIN2+ during median follow-up of 17.2 years [IQR 14.6]. In total, 1305 (66%) women were exposed to immunosuppressive drugs (IM 58%, BIO 40%, IM and BIO 33%). CIN2+ risk increased per year of exposure to IM (HR 1.16, 95% CI 1.08–1.25). No association was observed between cumulative exposure to BIO or both BIO and IM and CIN2+. In multivariate analysis, smoking (HR 2.73, 95%CI 1.77–4.37) and 5-yearly screening frequency (HR 1.74, 95% CI 1.33–2.27) were also risk factors for CIN2+ detection. Conclusion: Cumulative exposure to IM is associated with increased risk of CIN2+ in women with IBD. In addition to active counselling of women with IBD to participate in cervical screening programs, further assessment of the benefit of intensified screening of women with IBD on long-term IM exposure is warranted.

Published
2023

16. P503 The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ

Author

Rezazadeh Ardabili, A, primary, van Esser, D, additional, Wintjens, D, additional, Cilissen, M, additional, Deben, D, additional, Mujagic, Z, additional, Russ, F, additional, Stassen, L, additional, van Bodegraven, A, additional, Wong, D, additional, Winkens, B, additional, Jonkers, D, additional, Romberg-Camps, M, additional, and Pierik, M, additional

Published
2023
Full Text
View/download PDF

19. P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations

Author

Schreiber, S W, primary, Danese, S, additional, Dignass, A, additional, Domènech, E, additional, Fantini, M, additional, Ferrante, M, additional, Halfvarson, J, additional, Hart, A, additional, Magro, F, additional, Lees, C, additional, Leone, S, additional, Pierik, M, additional, Field, P, additional, Schofield, H, additional, and Peyrin-Biroulet, L, additional

Published
2023
Full Text
View/download PDF

20. P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial

Author

Van Linschoten, R, primary, Jansen, F, additional, Pauwels, R, additional, Smits, L, additional, Atsma, F, additional, Kievit, W, additional, de Jong, D, additional, de Vries, A, additional, Boekema, P, additional, West, R, additional, Bodelier, A, additional, Gisbertz, I, additional, Wolfhagen, F, additional, Romkens, T, additional, Lutgens, M, additional, van Bodegraven, A, additional, Oldenburg, B, additional, Pierik, M, additional, Russel, M, additional, de Boer, N, additional, Mallant-Hent, R, additional, ter Borg, P, additional, van der Meulen-de Jong, A, additional, Jansen, J, additional, Jansen, S, additional, Tan, A, additional, van der Woude, C J, additional, and Hoentjen, F, additional

Published
2023
Full Text
View/download PDF

21. P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings

Author

Burisch, J, primary, Zhao, M, additional, Odes, S, additional, De Cruz, P, additional, Vermeire, S, additional, Bernstein, C N, additional, Kaplan, G G, additional, Duricova, D, additional, Greenberg, D, additional, Melberg, H O, additional, Watanabe, M, additional, Ahn, H S, additional, Targownik, L, additional, Pittet, V E H, additional, Annese, V, additional, Park, K, additional, Konstantinos H, K H, additional, Høivik, M L, additional, Krznaric, Z, additional, Chaparro, M, additional, Loftus, E V, additional, Lakatos, P L, additional, Gisbert, J P, additional, Bemelman, W, additional, Moum, B, additional, Gearry, R B, additional, Kappelman, M D, additional, Hart, A, additional, Pierik, M, additional, Andrews, J, additional, Ng, S, additional, D'Inca, R, additional, and Munkholm, P, additional

Published
2023
Full Text
View/download PDF

26. Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study

Author

Nissen, Loes H C, Derikx, Lauranne A A P, Jacobs, Anouk M E, van Herpen, Carla M, Kievit, Wietske, Verhoeven, Rob, van den Broek, Esther, Bekers, Elise, van den Heuvel, Tim, Pierik, Marieke, Rahamat-Langendoen, Janette, Takes, Robert P, Melchers, Willem J G, Nagtegaal, Iris D, Hoentjen, Frank, de Jonge, E E C, Natte, R, Nijhuis, E W P, Peutz-Kootstra, C, Roelofs, J J T H, Willems, S M, Willig, A P, van Bodegraven, A A, Tan, A C I T L, Meeuse, J J, van der Meulen–de Jong, A E, Oldenburg, B, Loffeld, B C A J, Durfeld, B M, van der Woude, C J, Cahen, D L, D’Haens, G, Janik, D, Mares, W G M, Gilissen, L P L, Wolters, F L, Dijkstra, G, Erkelens, G W, Tang, T J, Breumelhof, R, Smalbraak, H J T, Thijs, J C, Voskuil, J H, Kuyvenhoven, J P, Vecht, J, Rijk, M C M, Janssen, J M, Sarneel, J T, Tjhie-Wensing, J W M, Lai, J Y L, Vlasveld, L T, Oostenbrug, L E, Gerretsen, M, Van Herwaarden, M A, Mahmmod, N, Russel, M G V M, Grubben, M J A L, Vu, M K, Verhulst, M L, Dewint, P, Stokkers, P C F, Bus, P J, Wismans, P J, van der Haeck, P W E, Stuyt, R J L, Zeijen, R N M, Dahlmans, R P M, Vandebosch, S, Romkens, T E H, Moolenaar, W, ten Hove, W R, Boot, H, van der Linde, K, Wahab, P, de Boer, S Y, Thurnau, K, Thijs, W J, Josemanders, D F G M, West, R L, Pierik, M J, Depla, A C T M, Keulen, E T P, de Boer, W A, Naber, A H J, Vermeijden, J R, Mallant-Hent, R C, Beukers, R, Ter Borg, P C J, Halet, E C R, Bruin, K F, Linskens, R K, and Bruins Slot, W

Published
2018
Full Text
View/download PDF

33. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life

Author

Kanis, S.L., Modderman, S., Escher, J.C., Erler, N., Beukers, R., Boer, N. de, Bodelier, A., Depla, A.C.T.M., Dijkstra, G., Dijk, A.B.R.M. van, Gilissen, L., Hoentjen, F., Jansen, J.M., Kuyvenhoven, J., Mahmmod, N., Mallant-Hent, R.C., Meulen-de Jong, A.E. van der, Noruzi, A., Oldenburg, B., Oostenbrug, L.E., Borg, P.C.J. ter, Pierik, M., Romberg-Camps, M., Thijs, W., West, R., Lima, A. de, Woude, C.J. van der, Initiative Crohns Colitis ICC, Groningen Institute for Organ Transplantation (GIOT), Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health, Gastroenterology & Hepatology, Pediatrics, Epidemiology, Gastroenterology and hepatology, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Pediatrics, AZATHIOPRINE, INTRAUTERINE EXPOSURE, Azathioprine, Disease, Inflammatory bowel disease, THERAPIES, Child Development, Patient Admission, Neoplasms, non-steroidal anti-inflammatory drugs, Netherlands, education.field_of_study, Vaccines, Thiopurine methyltransferase, biology, Mercaptopurine, Gastroenterology, WOMEN, Ulcerative colitis, Anti-Bacterial Agents, THIOPURINES, PREGNANCY, Child, Preschool, Prenatal Exposure Delayed Effects, Infant, Small for Gestational Age, Premature Birth, Drug Therapy, Combination, Female, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug, Adult, medicine.medical_specialty, Population, Infections, Drug Prescriptions, Autoimmune Diseases, Congenital Abnormalities, IMMUNOGLOBULINS, Gastrointestinal Agents, SDG 3 - Good Health and Well-being, INFLIXIMAB, medicine, Humans, education, Retrospective Studies, Pregnancy, business.industry, Cesarean Section, Inflammatory Bowel Disease, Adalimumab, Infant, Newborn, Infant, Retrospective cohort study, medicine.disease, Inflammatory Bowel Diseases, TRANSPORT, Pregnancy Complications, biology.protein, Tumor Necrosis Factor Inhibitors, business, TNF-ALPHA DRUGS
Abstract

ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies.ResultsWe included 1000 children born to 626 mothers (381 (61%) Crohn’s disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population.ConclusionIn our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies.

Published
2021

34. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease

Author

Severs, M., Mangen, M-J. J., van der Valk, M. E., Fidder, H. H., Dijkstra, G., van der Have, M., van Bodegraven, A. A., de Jong, D. J., van der Woude, C. J., Romberg-Camps, M. J. L., Clemens, C. H. M., Jansen, J. M., van de Meeberg, P. C., Mahmmod, N., Ponsioen, C. Y., Vermeijden, J. R., van der Meulen- de Jong, A. E., Pierik, M., Siersema, P. D., and Oldenburg, B.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results